Abstract
PurposeTo evaluate the short‐term efficacy of intravitreal anti‐VEGF for the treatment of subretinal fluid (SRF) and/or pigment epithelium detachment (PED) secondary to chronic central serous chorioretinopathy (CSR).MethodsSixteen patients were treated with intravitreal injections of anti‐VEGF at 6‐ to 8‐week intervals until SRF and/or PED resolved. Main outcomes were Best‐Corrected Visual Acuity (BCVA), central retinal thickness (CRT) measured with optical coherence tomography (OCT), performed at 6‐ to 8‐week intervals and number of injections. Fluorescein angiography was performed at baseline visit and thereafter depending on clinical and OCT findings.ResultsPatients received 3.16 (range: 1–15) intravitreal injections of anti‐VEGF on average during a follow‐up of 22 +/‐ 2 weeks. Mean BCVA increased by 11.2 letters and mean CRT decreased significantly over follow‐up from 396.68 µm at baseline to 250.36 µm on last visit. 5 patients (31.25%) showed complete resolution of subretinal fluid and PED, 6 patients (37.5%) had persistent SRF and 5 patients (31.25%) had persistent PED.ConclusionsAnatomic and functional improvement following intravitreal anti‐VEGF injections suggest that vascular endothelial growth factor (VEGF) may be involved in fluid leakage in patients with chronic CSR. The results suggest a possible role for anti‐VEGF agents in the treatment of chronic CSR.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
